Diabetes Care Stocks List Ranked for 2024 | NYSE,

Symbol	Grade	Name	% Change
NVO	F	Novo Nordisk A/S	-2.51
TNDM	D	Tandem Diabetes Care, Inc.	1.96
PRGO	C	Perrigo Company	-0.26

Symbol	Grade	Name	Weight
OZEM	F	Roundhill GLP-1 & Weight Loss ETF	17.04
THNR	F	Amplify Weight Loss Drug & Treatment ETF	13.16
PPH	D	Market Vectors Pharmaceutical ETF	8.18
BELT	B	BlackRock Long-Term U.S. Equity ETF	5.28
AADR	A	WCM BNY Mellon Focused Growth ADR ETF	4.85

Compare ETFs

Date	Stock	Title
Nov 21	TNDM	Tandem Diabetes Care Announces Upcoming Conference Presentations
Nov 21	NVO	Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
Nov 21	NVO	Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
Nov 21	NVO	Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop
Nov 20	NVO	More companies covering weight loss drugs for their employees
Nov 20	NVO	Weight loss drug makers want more insurance plans to cover Wegovy and Zepbound
Nov 20	NVO	Is Novo Nordisk Stock a Buy Right Now?
Nov 20	NVO	RFK Jr. Sparks New Worries About Obesity Drugs. Here’s What Investors Should Focus on Instead.
Nov 19	NVO	Novo Nordisk semaglutide phase 3 trial for MASH meets primary endpoints
Nov 19	NVO	Sector Update: Health Care Stocks Decline
Nov 19	NVO	Novo Nordisk Unusual Options Activity For November 19
Nov 19	NVO	Sector Update: Health Care Stocks Mixed Tuesday Afternoon
Nov 19	NVO	Novo Erases 2024 Gain, Wiping Out $210 Billion in Value
Nov 19	NVO	Market Chatter: Eli Lilly, Novo Nordisk Press Employers to Cover the Cost of Weight-Loss Drugs
Nov 19	PRGO	Perrigo Company: Great Combination Of Future Growth With A Low Valuation
Nov 19	NVO	Employers Get Pressure to Pay for Drugs Like Wegovy
Nov 18	NVO	RFK Jr.'s HHS nomination sparks concern over pharma stocks
Nov 18	NVO	Novo Nordisk reportedly launches Wegovy in China
Nov 18	NVO	How Robert F. Kennedy Jr. could impact the healthcare sector as secretary of health
Nov 18	NVO	Market Chatter: Eli Lilly, Novo Nordisk Obesity Drugs Covered Mostly by Medicaid, Analysts Say

Diabetes Care: Diabetes Care is a monthly peer-reviewed medical journal published since 1978 by the American Diabetes Association. The journal covers research in the following five categories: 1) clinical care/education/nutrition/psychosocial research, 2) epidemiology/health services research, 3) emerging treatments and technologies, 4) pathophysiology/complications, and 5) cardiovascular and metabolic risk. The journal also publishes clinically relevant review articles, letters to the editor, and commentaries.According to the Journal Citation Reports, the journal has a 2017 impact factor of 13.397 ranking it fifth out of 138 journals in the category "Endocrinology & Metabolism."